I have not seen any posting implying that Repros would not be able to get an IND thru the FDA for Anemia. Rather, it serves as yet more evidence of "speed bumps," that were not apparent before, and which cast doubt upon the entire pipeline. yes, because most small, 6 person startup biotechs have smooth sailing and speedbumps are severely rare. these guys are crooks. NOT!!! every intelligent investor who buys small biotech staocks knows this!!!! I left (whether temporarily or permanently) please be gone for good because the speedbumps started materializing en masse, beginning with Androxal and further exacerbated by the delays with Proellex Fibroid trials. Now we have a delay with Anemia (I hope no one tries to say it isn't a delay, because the company touted this indication, with "possible fast-track status" some time ago). 1- it's not a delay if it's a new indication completely, and 2- I'd paypal you $50 if you could prove that management said "fast track" in the same sentence with the anemia indication. They haven't. You know it. It's all on track... I believe management is losing a slight amount of credibility, at least with me. good. you sold. LEAVE PLEASE AND FORGET RPRX I may choose to reinvest if/when clarity finally emerges. An accepted FDA IND for Anemia would help, but that is months away. An accepted PIII Fibroid trial design would help, but that is months away. (This is my biggest angst, since the PIII trials should've already commenced). I have written-off Androxal for the foreseeable future.
One has to believe that the share price belies these observations... {the share doesn't belie these observations, the share price believes these speculations, and they're dead wrong. DED ROUNG!!!!!
Market Data 
Markets 
